BICO Group AB Class B (CLLKF) AI Stock Analysis

BICO Group AB Class B

(Other OTC:CLLKF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin ExpansionThe sharp improvement in gross margin and adjusted EBITDA margin indicates stronger unit economics and better operating discipline. If sustained, this progress can improve earnings quality, support reinvestment in product development, and strengthen the company’s path toward durable profitability.

Negative Factors

Persistent UnprofitabilityDeeply negative profitability shows that revenue growth and gross-margin improvement have not yet translated into sustainable earnings. Continued losses can consume financial resources, constrain reinvestment, and increase the risk that future growth requires additional financing or dilution.

BICO Group AB Class B (CLLKF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $175.62M
Dividend Yield: ―
Average Volume (3M): 1,381
Price to Earnings (P/E): -2.1
Beta (1Y): 0.39
Revenue Growth: -5.77%
EPS Growth: -174.08%
Country: US
Employees: 554
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

BICO Group AB Class B Business Overview & Revenue Model

Company Description

BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. T...

BICO Group AB Class B Earnings Call Summary

Earnings Call Date:Aug 18, 2026(Q2-2026)|% Change Since:45.67%|Next Earnings Date:Feb 24, 2021

Earnings Call SentimentNeutral

The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.

Positive Updates

Quarterly Revenue and Organic Growth

Sales of SEK 336 million in Q2 2026, representing organic growth of 7% in local currencies and reported growth of 4% after currency headwinds.

Negative Updates

Project-Based Business Execution Challenges

Ongoing execution challenges in the U.S.-based integrated lab automation (project) business led to rightsizing of the U.S. organization. Legacy multi-year projects have caused delays and uneven, lumpy revenue recognition.

Company Guidance

The company did not provide formal forward-looking financial guidance, but offered directional expectations and several specific metrics: Q2 sales were SEK 336m (organic growth +7% in local currencies, total growth +4%), adjusted EBITDA SEK 20m (adjusted EBITDA margin 6%, a +21 percentage-point improvement), EBITDA SEK 60m, gross margin 59% (vs 44% a year ago), consumables +10%, and operating cash flow was negative SEK 53m (driven by a net working capital change of -SEK 54m: receivables +SEK 15m, inventories +SEK 6m, payables -SEK 33m). Balance-sheet and cash metrics included cash reserves SEK 628m (SEK 57m restricted) and net cash SEK 207m (improved from net debt of -SEK 877m previously). Management expects working capital to normalize toward an industry standard of ~20% of sales over time, anticipates annualized savings of NOK 30m from the Lyon→Berlin consolidation (effects starting H2), and disclosed a Scienion deal with ~EUR 50m contracted over 10 years plus a license of EUR 10.6m to be recognized as revenue in Q3 (cash invoiced annually).

BICO Group AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CLLKF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.67B	33.84	15.23%	1.41%	1.95%	-8.91%
SE:BONEX	81Outperform	SEK 21.40B	78.69	29.00%	―	25.20%	79.34%
SE:XVIVO	64Neutral	SEK 6.46B	50.12	5.89%	―	17.83%	330.94%
SE:VITR	61Neutral	SEK 15.64B	-3.15	-61.57%	0.95%	-1.94%	-1223.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:OSSD	44Neutral	SEK 373.36M	-7.46	―	―	-2.61%	-0.28%

* Healthcare Sector Average

Performance Comparison

CLLKF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CLLKF	BICO Group AB Class B	2.54	-0.02	-0.70%
SE:VITR	Vitrolife AB	115.50	-26.84	-18.85%
SE:BONEX	BONESUPPORT HOLDING AB	325.00	113.80	53.88%
SE:CEVI	CellaVision AB	195.60	17.76	9.98%
SE:XVIVO	Xvivo Perfusion AB	205.00	22.50	12.33%
SE:OSSD	OssDsign AB	3.38	-9.51	-73.80%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BICO Group AB Class B AI Stock Analysis